Literature DB >> 15696168

Crystal structure of a soluble CD28-Fab complex.

Edward J Evans1, Robert M Esnouf, Raquel Manso-Sancho, Robert J C Gilbert, John R James, Chao Yu, Janet A Fennelly, Cheryl Vowles, Thomas Hanke, Björn Walse, Thomas Hünig, Poul Sørensen, David I Stuart, Simon J Davis.   

Abstract

Naive T cell activation requires signaling by the T cell receptor and by nonclonotypic cell surface receptors. The most important costimulatory protein is the monovalent homodimer CD28, which interacts with CD80 and CD86 expressed on antigen-presenting cells. Here we present the crystal structure of a soluble form of CD28 in complex with the Fab fragment of a mitogenic antibody. Structural comparisons redefine the evolutionary relationships of CD28-related proteins, antigen receptors and adhesion molecules and account for the distinct ligand-binding and stoichiometric properties of CD28 and the related, inhibitory homodimer CTLA-4. Cryo-electron microscopy-based comparisons of complexes of CD28 with mitogenic and nonmitogenic antibodies place new constraints on models of antibody-induced receptor triggering. This work completes the initial structural characterization of the CD28-CTLA-4-CD80-CD86 signaling system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696168     DOI: 10.1038/ni1170

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  69 in total

Review 1.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

2.  Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor.

Authors:  Sergei Radaev; Zhongcheng Zou; Pavel Tolar; Khanh Nguyen; AnhThao Nguyen; Peter D Krueger; Nicole Stutzman; Susan Pierce; Peter D Sun
Journal:  Structure       Date:  2010-08-11       Impact factor: 5.006

Review 3.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

4.  Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Authors:  J Rohr; S Guo; J Huo; A Bouska; C Lachel; Y Li; P D Simone; W Zhang; Q Gong; C Wang; A Cannon; T Heavican; A Mottok; S Hung; A Rosenwald; R Gascoyne; K Fu; T C Greiner; D D Weisenburger; J M Vose; L M Staudt; W Xiao; G E O Borgstahl; S Davis; C Steidl; T McKeithan; J Iqbal; W C Chan
Journal:  Leukemia       Date:  2015-12-31       Impact factor: 11.528

5.  Cutting edge: A role for inside-out signaling in TCR regulation of CD28 ligand binding.

Authors:  Mariano Sanchez-Lockhart; Minsoo Kim; Jim Miller
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

6.  CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Ctheta in the immunological synapse.

Authors:  Su-Yi Tseng; Mengling Liu; Michael L Dustin
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 7.  Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.

Authors:  N Beyersdorf; T Hanke; T Kerkau; T Hünig
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

8.  Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma.

Authors:  Grzegorz B Gmyrek; Jeanette Pingel; Jaehyuk Choi; Jonathan M Green
Journal:  Cell Immunol       Date:  2017-07-10       Impact factor: 4.868

Review 9.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 10.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.